32 results
424B5
ACXP
Acurx Pharmaceuticals Inc
15 Nov 23
Prospectus supplement for primary offering
4:49pm
patients as originally planned. The early termination was further based on the evidence of meeting the treatment goals of eliminating the infection … of meeting the treatment goals of eliminating the infection with an acceptable adverse event profile.
The SAB noted that 10 out of 10 patients
424B3
9402crvm00 gi0oi
13 Jul 23
Prospectus supplement
4:32pm
424B5
2nrs332u
17 May 23
Prospectus supplement for primary offering
4:25pm
PRE 14A
ecu35 ul71k8u
17 Apr 23
Preliminary proxy
4:05pm
424B3
ne1o5iaxg5x4835bi
23 Sep 22
Prospectus supplement
8:19am
424B5
kjjwt1xnnsm0u gfef
25 Jul 22
Prospectus supplement for primary offering
4:26pm
S-3
42dwks1
1 Jul 22
Shelf registration
8:46am
DEF 14A
z0c5bsmn
25 Apr 22
Definitive proxy
4:06pm